Corey M Gill1, Priscilla K Brastianos2. 1. Icahn School of Medicine at Mount Sinai, New York, New York. 2. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Highlight recent data in lung and breast cancer leptomeningeal disease and address clinical trials that are open for patients. RECENT FINDINGS: Patients with lung and breast cancer leptomeningeal disease have survival outcomes of less than 1 year, despite advances in treatment strategy. Efforts to develop liquid biopsy biomarkers of disease progression from cerebrospinal fluid and plasma are underway. There are over 10 clinical trials open for patients with leptomeningeal disease, half of which use immunotherapy. SUMMARY: Consortium-based, multicenter clinical trials for patients with leptomeningeal disease are urgently needed to expand the treatment armamentarium.
PURPOSE OF REVIEW: Highlight recent data in lung and breast cancer leptomeningeal disease and address clinical trials that are open for patients. RECENT FINDINGS:Patients with lung and breast cancer leptomeningeal disease have survival outcomes of less than 1 year, despite advances in treatment strategy. Efforts to develop liquid biopsy biomarkers of disease progression from cerebrospinal fluid and plasma are underway. There are over 10 clinical trials open for patients with leptomeningeal disease, half of which use immunotherapy. SUMMARY: Consortium-based, multicenter clinical trials for patients with leptomeningeal disease are urgently needed to expand the treatment armamentarium.
Authors: Margaux Wooster; Julia E McGuinness; Kathleen M Fenn; Veena M Singh; Lauren E Franks; Shing Lee; David Cieremans; Andrew B Lassman; Dawn L Hershman; Katherine D Crew; Melissa K Accordino; Meghna S Trivedi; Fabio Iwamoto; Mary R Welch; Aya Haggiagi; Robbie D Schultz; Lan Huynh; Edgar Sales; Deanna Fisher; Julie Ann Mayer; Teri Kreisl; Kevin Kalinsky Journal: Clin Breast Cancer Date: 2021-11-14 Impact factor: 3.078
Authors: Rachna Malani; Martin Fleisher; Priya Kumthekar; Jeffrey Raizer; Elena Pentsova; Xuling Lin; Antonio Omuro; Morris D Groves; Nancy U Lin; Michelle Melisko; Andrew B Lassman; Suriya Jeyapalan; Andrew Seidman; Anna Skakodub; Adrienne Boire; Lisa M DeAngelis; Marc Rosenblum Journal: J Neurooncol Date: 2020-06-06 Impact factor: 4.130